What intangible assets matter most in pharmaceutical and biotech companies?

Full Explanation

Pharmaceutical and biotechnology companies are among the most intangible-intensive industries, with 80-95% of enterprise value typically attributable to non-physical assets. The most significant intangible assets include: patented compounds and formulations (valued via RFR using pharmaceutical royalty rate benchmarks, with illustrative ranges of 3-8% for established drugs and 15-25% for novel compounds; the actual rate depends on the comparable licence evidence), in-process research and development (valued via probability-weighted MPEEM, with success probabilities varying by clinical trial phase — approximately 10% for Phase I, 20-30% for Phase II, 50-70% for Phase III), marketing authorisations and regulatory approvals (the FDA, EMA, or MHRA approval itself represents significant value due to the time and cost of obtaining it), and proprietary manufacturing processes (valued via cost approach or RFR if licensing comparables exist). Customer relationships in pharma may include relationships with hospital systems, pharmacy chains, or wholesale distributors, though their relative value is often lower than in other industries because demand is driven primarily by the product rather than the sales relationship. Data exclusivity periods and orphan drug designations provide additional intangible value through regulatory protection. PPAs in pharma require deep industry expertise because the probability-weighting of pipeline assets and the selection of appropriate royalty rates for compounds at different development stages are highly specialised judgements.

Related Glossary Terms

Related Questions